Partners

Our International Network of Partners

Meeting our ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. We are extremely grateful.

map

Medical Institutions

Prostate Cancer Centre (Calgary)

Northern Alberta Urology Centre (Edmonton)

Alberta Health Services (Alberta)

Vancouver Prostate Cancer Centre (Vancouver)

The Prostate Centre at The Princess Margaret Hospital (Toronto)

CHUM Groupe de soutien du cancer de la prostate (Montreal)

London Regional Cancer Program (London, ON)

Technology Platforms

Malvern (UK)

APOGEE (UK)

Nanosight

BGI Genomics (China)

Precision Nanosystems (BC)

Universities

University of Alberta (Edmonton, AB)

University of Calgary (Calgary, AB)

Western University (London, ON)

Dalhousie University (Halifax, NS)

University of Toronto (Toronto, ON)

Vanderbilt University (Nashville, TN)

Case Western Reserve University (Cleveland, OH)

Fraunhofer ITEM-R (Regensburg, Germany)

Biorepositories

Alberta Cancer Research Biobank (Calgary, Edmonton)

Australian Prostate Cancer BioResource (Australia: Melbourne, Sydney, Brisbane and Adelaide)

OICR Tumour Bank (Ontario)

Tomorrow Project 

UHN GU BioBank

Canadian Biosample Repository

Canadian Prostate Cancer Biomarker Network

Financial Resources

Alberta Cancer Foundation (Alberta)

Movember Foundation (Australia, Canada)

Terry Fox Research Institute (Canada)

Motorcycle Ride for Dad (Canada)

Prostate Cancer Canada

Alberta Innovates Health Solutions – Collaborative Research and Innovation opportunities

Alberta Lymphedema Network (Edmonton, Alberta)

University Hospital Foundation – J & J Partnership

Support Groups

Prostate Cancer Canada Network (Canada)

Prostate Cancer Canada Network (Calgary)

Prostate Cancer Canada Network (Edmonton)

The Calgary Prostate Cancer Centre has the highest accrual for a novel ultrasound study in prostate cancer

“We have enrolled over 400 patients at our site, reaching our enrollment goal much faster than all other sites across North America. We are now planning on adding in 250 more patients to this trial because of the encouraging results found with the first arm of the trial. Our site tied with the highest accrual goal and surpassed all other sites to meet our enrollment goal.”

The study is a “Multi-Center trial of high-resolution transrectal ultrasound versus standard low-resolution transrectal ultrasound for the identification of clinically significant prostate cancer”

The only definitive method for diagnosing prostate cancer is through a prostate biopsy. This procedure includes the use of an ultrasound machine to guide both freezing needles and biopsy needles into the prostate. The ultrasound machine that is currently in use is a low-resolution ultrasound machine which means that although it is good at seeing the entire prostate gland to guide the needles, it is often unable to visualize the prostate in enough detail to be able to see different lesions and areas of concern within it. Thus, many biopsy samples are taken systematically with two samples from each section of the prostate. Recently a new ultrasound machine has been created that gives images of the prostate with much higher resolution, allowing the radiologist performing the biopsy to see details within the prostate that were previously inaccessible. A study using this new high-resolution ultrasound machine is being completed at the Prostate Cancer Centre to compare the adequacy of this new machine to detect prostate cancer over the standard low-resolution machine. Over 650 patients will be enrolled in this study!

pcc-logo_2x

- Eric Hyndman

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.